Dennis L Guberski

US Patent:

20030194438, Oct 16, 2003

Filed:

Apr 10, 2003

Appl. No.:

10/410940

Inventors:

Albert Prescott - Groton MA, US
Edward Kislauskis - Medway MA, US
Dennis Guberski - Rutland MA, US

International Classification:

A61K031/728
A61K031/60
A61K031/485
A61K031/192
A61K031/16
A61K009/22

US Classification:

424/468000, 514/054000, 514/165000, 514/570000, 514/629000, 514/282000

Abstract:

An extended release analgesic for controlling pain comprised of an opioid or non-opioid analgesic drug ionically bound to hyaluronic acid, poly--glutamic acid or other ionic polymers, and injected into a body either subcutaneously, intramuscularly or intraperitoneally, utilizing counter-ions of different valences to control the rate of release into the body.

US Patent:

20060035853, Feb 16, 2006

Filed:

Jan 7, 2005

Appl. No.:

11/032487

Inventors:

Kejian Yang - Northborough MA, US
Barbara Whalen - Shrewsbury MA, US
Edward Kislauskis - Medway MA, US
Dennis Guberski - Rutland MA, US

Assignee:

Biomedical Research Models, Inc. - Worcester MA
Oral Vaccine Technologies , Inc, - Las Vegas NV

International Classification:

A61K 48/00
A61K 9/127

US Classification:

514044000, 424093200, 424450000

Abstract:

The invention relates to methods and reagents for immunizing animals to elicit specific cellular and humoral immune-responses against specific antigens, such as viral antigens, including HBsAg antigen. The invention provides methods of using specifically prepared immunogen in fresh or lyophilized liposome, proper routes of administration of the immunogen, proper doses of the immunogen, and specific combinations of heterologous immunization including DNA priming in one administration route followed by liposome-mediated protein antigen boost in a different route to tailor the immune responses in respects of enhancing cell mediated immune response, cytokine secretion, humoral immune response, immune protection and selective skewing of T helper responses to be Th1, Th2, or a mixed or balanced Th response.

US Patent:

20060179499, Aug 10, 2006

Filed:

Aug 19, 2005

Appl. No.:

11/207315

Inventors:

Rebecca Tirabassi - Sturbridge MA, US
Edward Kislauskis - Medway MA, US
Joan Flanagan - Worcester MA, US
Dennis Guberski - Rutland MA, US

International Classification:

A01K 67/027

US Classification:

800014000

Abstract:

The instant invention relates to methods for generating a non-human animal model for a diabetic complication. The invention further relates to screening methods for therapeutics of diabetic complications using the animal model generated by the methods of the invention.

US Patent:

20120027841, Feb 2, 2012

Filed:

Mar 9, 2011

Appl. No.:

13/044379

Inventors:

Kejian YANG - Northborough MA, US
Dennis L. Guberski - Rutland MA, US

Assignee:

Biomedical Research Models, Inc. - Worcester MA

International Classification:

A61K 39/245
A61P 31/22
A61K 9/127

US Classification:

424450, 4242311

Abstract:

The invention provides methods and kits for immunizing animals (e.g. mammals) against viral antigens, including herpes-simplex virus type 2. The protective immune response elicited by the methods and kits of the invention is characterized by robust humoral, cellular, and mucosal immunity. In particular, the invention provides a heterologous immunization method comprising a priming DNA vaccine encoding an antigen and a boosting protein vaccine, in which the protein form of the antigen is encapsulated in liposomes. Methods of preventing primary acute, latent and recurrent viral infections, such as that caused by HSV-2 virus, and methods of providing passive protective immunity against a viral pathogen such as HSV-2 virus to a mammal are also disclosed.

US Patent:

20130195961, Aug 1, 2013

Filed:

Mar 9, 2011

Appl. No.:

13/583845

Inventors:

Kejian Yang - Northborough MA, US
Dennis I. Guberski - Rutland MA, US

International Classification:

A61K 39/245

US Classification:

424450, 4241861, 4241601

Abstract:

Methods and kits for immunizing animals (e.g. mammals) against viral antigens, including herpes-simplex virus type 2 are provided. The protective immune response elicited by the methods and kits is characterized by robust humoral, cellular, and mucosal immunity. In particular, a heterologous immunization method comprising a priming DNA vaccine encoding an antigen and a boosting protein vaccine, in which the protein form of the antigen is encapsulated in liposomes is provided. Methods of preventing primary acute, latent and recurrent viral infections, such as that caused by HSV-2 virus, and methods of providing passive protective immunity against a viral pathogen such as HSV-2 virus to a mammal are also disclosed.

US Patent:

20180193448, Jul 12, 2018

Filed:

Aug 11, 2017

Appl. No.:

15/674929

Inventors:

- Worcester MA, US
Dennis L. GUBERSKI - Worcester MA, US

International Classification:

A61K 39/245
A61K 31/7088
A61K 39/00
A61K 39/12
A61K 9/127

Abstract:

Methods and kits for immunizing animals (e.g. mammals) against viral antigens, including herpes-simplex virus type 2 are provided. The protective immune response elicited by the methods and kits is characterized by robust humoral, cellular, and mucosal immunity. In particular, a heterologous immunization method comprising a priming DNA vaccine encoding an antigen and a boosting protein vaccine, in which the protein form of the antigen is encapsulated in liposomes is provided. Methods of preventing primary acute, latent and recurrent viral infections, such as that caused by HSV-2 virus, and methods of providing passive protective immunity against a viral pathogen such as HSV-2 virus to a mammal are also disclosed.

US Patent:

20180008695, Jan 11, 2018

Filed:

Sep 22, 2017

Appl. No.:

15/713019

Inventors:

- Worcester MA, US
Dennis L. GUBERSKI - Worcester MA, US

International Classification:

A61K 39/12
C07K 14/035
C07K 14/005
A61K 38/00
A61K 39/00
A61K 39/245
C07K 16/08
C07K 14/03

Abstract:

The invention provides methods and kits for inducing a therapeutic immunity in animals (e.g. mammals) against viral antigens, including herpes-simplex virus type 2. In particular, the invention provides a method of treating animals with an established HSV-2 infection by administering a therapeutic vaccine comprising a priming dose of a nucleic acid encoding an HSV-2 antigen, an initial or first boosting dose comprising the protein form of the antigen encapsulated in liposomes, and one or more subsequent boosting doses comprising both the nucleic acid encoding the HSV-2 antigen and the liposomal-encapsulated protein antigen.

US Patent:

20170258894, Sep 14, 2017

Filed:

Oct 21, 2016

Appl. No.:

15/299876

Inventors:

- Worcester MA, US
Dennis L. GUBERSKI - Rutland MA, US

International Classification:

A61K 39/245
A61K 31/7088
A61K 39/12
A61K 9/127
A61K 39/00

Abstract:

The invention provides methods and kits for immunizing animals (e.g. mammals) against viral antigens, including herpes-simplex virus type 2. The protective immune response elicited by the methods and kits of the invention is characterized by robust humoral, cellular, and mucosal immunity. In particular, the invention provides a heterologous immunization method comprising a priming DNA vaccine encoding an antigen and a boosting protein vaccine, in which the protein form of the antigen is encapsulated in liposomes. Methods of preventing primary acute, latent and recurrent viral infections, such as that caused by HSV-2 virus, and methods of providing passive protective immunity against a viral pathogen such as HSV-2 virus to a mammal are also disclosed.